-
Signature
-
/s/ Tobin Schilke, as attorney-in-fact
-
Issuer symbol
-
CRNX
-
Transactions as of
-
12 Jun 2025
-
Net transactions value
-
-$2,850,799
-
Form type
-
4
-
Filing time
-
16 Jun 2025, 16:48:09 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Betz Stephen F. |
Chief Scientific Officer |
C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO |
/s/ Tobin Schilke, as attorney-in-fact |
16 Jun 2025 |
0001886575 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
CRNX |
Common Stock |
Options Exercise |
$136,613 |
+71,525 |
+66% |
$1.91 |
180,551 |
12 Jun 2025 |
Direct |
F1 |
| transaction |
CRNX |
Common Stock |
Options Exercise |
$154,466 |
+16,645 |
+9.2% |
$9.28 |
197,196 |
12 Jun 2025 |
Direct |
|
| transaction |
CRNX |
Common Stock |
Sale |
$3,141,877 |
-97,483 |
-49% |
$32.23 |
99,713 |
12 Jun 2025 |
Direct |
F2, F3 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
CRNX |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-71,525 |
-40% |
$0.000000 |
108,514 |
12 Jun 2025 |
Common Stock |
71,525 |
$1.91 |
Direct |
F4 |
| transaction |
CRNX |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-16,645 |
-22% |
$0.000000 |
58,198 |
12 Jun 2025 |
Common Stock |
16,645 |
$9.28 |
Direct |
F5 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: